Super rapid acting insulin and inhaled insulin

September 9, 2013- Interviewed by Steven E. Greer, MD

Jay Skyler, MD, PhD, Deputy Director of the Diabetes Research Institute at The University of Miami, and Chairman of the NIH’s TrialNet,┬ádiscusses the “prandial problem” that requires “super rapid acting” insulin, and some new insulins in clinical trials, including inhaled Afrezza.

Disclosure: Jay Skyler, MD, has disclosed the following relevant financial relationships:
Served as an advisor/consultant for: Sanofi-Aventis; Gilead Sciences, Inc., Merck & Co., Inc.; Takeda Pharmaceuticals North America, Inc.; Cebix, Incorporated; Lilly USA, LLC, Dr. Skyler is an unpaid member of the scientific advisory board of MannKind

Received grants for clinical research from: Halozyme Therapeutics; Intuity Medical, Inc.; Mesoblast Limited; Osiris Therapeutics, Inc.

Owns stocks, stock options, or bonds from: Dexcom, Inc.; Amylin Pharmaceuticals, Inc.; Moerae Matrix; Opko Health Inc.; Patton Medical Devices, LP

This entry was posted in - Biotech, - Pharma, Diabetes and endocrinology, Univ Miami. Bookmark the permalink.

Leave a Reply